Catalyst's Firdapse Expansion To Myasthenia Gravis In Doubt, LEMS Launch Disrupted By COVID-19
You may also be interested in...
Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.
Argenx's efgartigimod, an antibody fragment that blocks FcRn, looks most likely to be the first drug to challenge Alexion's Soliris in the myasthenia gravis market after the company presented more positive data from the ADAPT trial.
Roivant will form a new "vant" company to develop and commercialize Pfizer's TL1A inhibitor for ulcerative colitis.